|
1
|
Lu FM and Zhuang H: Management of
hepatitis B in China. Chin Med J (EngI). 122:3–4. 2009.
|
|
2
|
Liang X, Bi S, Yang W, Wang L, Cui G, Cui
F, Zhang Y, Liu J, Gong X, Chen Y, et al: EpidemioIogicaI
serosurvey of hepatitis B in China-decIining HBV prevaIence due to
hepatitis B vaccination. Vaccine. 27:6550–6557. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Seeger C and Mason WS: Molecular biology
of hepatitis B virus infection. Virology. 479–480:672–686. 2015.
View Article : Google Scholar
|
|
4
|
Meng N, Gao X, Yan W, Wang M, Liu P, Lu
XD, Zhang SJ, Lu YQ and Tang WX: Efficacy of telbivudine in the
treatment of chronic hepatitis b and liver cirrhosis and its effect
on immunological responses. J Huazhong Univ Sci Technolog Med Sci.
35:230–234. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Neuman MG, Cohen LB and Nanau RM:
Hyaluronic acid as a non-invasive biomarker of liver fibrosis. Clin
Biochem. 49:302–15. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jiang YF, Ma J, He B, Li NP, Tang W and
Gong GZ: The therapeutic effect of Anluohuaxian capsule combined
with adefovir dipivoxil on patients with chronic hepatitis B and
influence on hepatic histology. Zhonghua Gan Zang Bing Za Zhi.
20:344–347. 2012.(In Chinese). PubMed/NCBI
|
|
7
|
You SP, Zhao J, Ma L, Tudimat M, Zhang SL
and Liu T: Preventive effects of phenylethanol glycosides from
Cistanche tubulosa on bovine serum albumin-induced hepatic fibrosis
in rats. Daru. 23:522015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Oztas E, Kuzu UB, Zengin NI, Kalkan IH,
Onder FO, Yildiz H, Celik HT, Akdogan M, Kilic MY, Koksal AS, et
al: Can Serum ST2 levels be used as a marker of fibrosis in chronic
Hepatitis B infection? Medicine (Baltimore). 94:e18892015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang Z, Wang G, Kang K, Wu G and Wang P:
The diagnostic accuracy and clinical utility of three noninvasive
models for predicting liver fibrosis in patients with HBV
Infection. PLoS One. 11:e01527572016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lok AS and McMahon BJ: Chronic hepatitis
B. Hepatology. 45:507–539. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hou YQ, Xu P, Zhang M, Han D, Peng L,
Liang DY, Yang S, Zhang Z, Hong J, Lou XL, et al: Serum decoy
receptor 3, a potential new biomarker for sepsis. Clin Chim Acta.
413:744–748. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liang D, Hou Y, Lou X and Chen H: Decoy
receptor 3 improves survival in experimental sepsis by suppressing
the inflammatory response and lymphocyte apoptosis. PLoS One.
10:e01316802015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Easterbrook PJ, Roberts T, Sands A and
Peeling R: Diagnosis of viral hepatitis. Curr Opin HIV AIDS.
12:302–314. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lambrecht J, Verhulst S, Mannaerts I,
Reynaert H and van Grunsven LA: Prospects in non-invasive
assessment of liver fibrosis: Liquid biopsy as the future
goldstandard? Biochim Biophys Acta. 1864:1024–1036. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu J, Ji Y, Ai H, Ning B, Zhao J, Zhang Y
and Dun G: Liver shear-wave velocity and serum fibrosis markers to
diagnosis hepatic fibrosis in patients with chronic vial Hepatitis
B. Korean J Radiol. 17:396–404. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cho HJ, Kim SS, Ahn SJ, Park JH, Kim DJ,
Kim YB, Cho SW and Cheong JY: Serum transferrin as a liver fibrosis
biomarker in patients with chronic hepatitis B. Clin Mol Hepatol.
20:347–354. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Alempijević T, Štulić M, Popovic D,
Culafic D, Dragasevic S and Milosavljevic T: The role of fecal
calprotectin in assessment of hepatic encephalopathy in patients
with liver cirrhosis. Acta Gastroenterol Belg. 77:302–305.
2014.PubMed/NCBI
|
|
18
|
Lin WW and Hsieh SL: Decoy receptor 3: A
pleiotropic immunomodulator and biomarker for inflammatory
diseases, autoimmube diseases and cancer. Biochem Pharmacol.
81:838–847. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Siakavellas SI, Sfikakis PP and Bamias G:
The TL1A/DR3/DcR3 pathway in autoimmune rheumatic diseases. Semin
Arthritis Rheum. 45:1–8. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim S, Kotoula V, Hytiroglou P, Zardavas D
and Zhang L: Significance of increased expression of decoy receptor
3 in chronic liver disease. Dig Liver Dis. 41:591–598. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bamias G, Kaltsa G, Siakavellas SI,
Papaxoinis K, Zampeli E, Michopoulos S, Zouboulis-Vafiadis I and
Ladas SD: High intestinal and systemic levels of decoy receptor 3
(DcR3)and its ligand TL1A in active ulcerative colitis. Chin
Immunol. 137:242–249. 2010. View Article : Google Scholar
|
|
22
|
Hou Y, Xu P, Lou X, Liang D, Zhang M,
Zhang Z and Zhang L: Serum decoy receptor 3 is a useful predictor
for the active status of chronic hepatitis B in hepatitis B e
antigen-negative patients. Tohoku J Exp Med. 230:227–232. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang M, Chen G, Dang Y and Luo D:
Significance of decoy receptor 3 in sera of hepatocellular
carcinoma patients. Ups J Med Sci. 115:232–237. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yoo S, Jang J, Kim S, Cho H and Lee MS:
Expression of DcR3 and its effects in kaposi's sarcoma-associated
herpesvirus-infected human endothelial cells. Intervirology.
55:45–52. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bamias G, Evangelou K, Vergou T,
Tsimaratou K, Kaltsa G, Antoniou C, Kotsinas A, Kim S, Gorgoulis V,
Stratigos AJ and Sfikakis PP: Upregulation and nuclear localization
of TNF-like cytokine 1A (TL1A) and its receptors DR3 and DcR3 in
psoriatic skin lesions. Exp Dermatol. 20:725–731. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hsieh SL and Lin WW: Decoy receptor 3: An
endogenous immubomudulator in cancer growth and inflammatory
reactions. J Biomed Sci. 24:392017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ho CH, Hsu CF, Fong PF, Tai SK, Hsieh SL
and Chen CJ: Epstein-Barr virus transcription activator Rta
upregulates decoy receptor 3 expression by binding to its promoter.
J Virol. 81:4837–4847. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ho CH, Chen CL, Li WY and Chen CJ: Decoy
receptor 3, upregulated by Epstein-Barr virus latent membrane
protein 1, enhances nasopharyngeal carcinoma cell migration and
invasion. Carcinogenesis. 30:1443–1451. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xia L, Tian D, Huang W, Zhu H, Wang J,
Zhang Y, Hu H, Nie Y, Fan D and Wu K: Upregulation of IL-23
expression in patients with chronic hepatitis B is mediated by the
HBx/ERK/NF-κB pathway. J Immunol. 188:753–764. 2012. View Article : Google Scholar : PubMed/NCBI
|
